Stevens Capital Management’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $228K | Sell |
406
-865
| -68% | -$555K | 0.04% | 206 |
|
|
2025
Q4 | $860K | Sell |
1,271
-340
| -21% | -$232K | 0.3% | 80 |
|
|
2025
Q3 | $1.03M | Buy |
1,611
+388
| +32% | +$236K | 0.14% | 107 |
|
|
2025
Q2 | $656K | Sell |
1,223
-1,598
| -57% | -$764K | 0.18% | 101 |
|
|
2025
Q1 | $1.19M | Buy |
2,821
+1,872
| +197% | +$813K | 0.29% | 69 |
|
|
2024
Q4 | $392K | Sell |
949
-579
| -38% | -$254K | 0.16% | 178 |
|
|
2024
Q3 | $772K | Buy |
+1,528
| New | +$742K | 0.11% | 89 |
|
|
2024
Q2 | – | Sell |
-5,574
| Closed | -$3.01M | – | 281 |
|
|
2024
Q1 | $3.01M | Buy |
5,574
+4,004
| +255% | +$2.19M | 0.59% | 35 |
|
|
2023
Q4 | $871K | Buy |
1,570
+286
| +22% | +$134K | 0.22% | 100 |
|
|
2023
Q3 | $561K | Buy |
+1,284
| New | +$640K | 0.16% | 143 |
|
|
2023
Q2 | – | Sell |
-2,535
| Closed | -$1.27M | – | 273 |
|
|
2023
Q1 | $1.27M | Buy |
2,535
+1,755
| +225% | +$840K | 0.31% | 45 |
|
|
2022
Q4 | $318K | Sell |
780
-131
| -14% | -$50.9K | 0.2% | 84 |
|
|
2022
Q3 | $297K | Buy |
+911
| New | +$335K | 0.19% | 102 |
|
|
2022
Q2 | – | Sell |
-3,074
| Closed | -$1.68M | – | 186 |
|
|
2022
Q1 | $1.68M | Buy |
3,074
+1,327
| +76% | +$698K | 0.37% | 65 |
|
|
2021
Q4 | $1.15M | Sell |
1,747
-203
| -10% | -$127K | 0.26% | 94 |
|
|
2021
Q3 | $1.21M | Buy |
+1,950
| New | +$1.31M | 0.51% | 45 |
|
|
2021
Q2 | – | Sell |
-555
| Closed | -$272K | – | 208 |
|
|
2021
Q1 | $272K | Buy |
+555
| New | +$278K | 0.15% | 93 |
|
|
2020
Q1 | – | Sell |
-13,478
| Closed | -$3.52M | – | 204 |
|
|
2019
Q4 | $3.52M | Buy |
+13,478
| New | +$3.55M | 0.33% | 84 |
|
|
2019
Q2 | – | Sell |
-13,893
| Closed | -$3.11M | – | 735 |
|
|
2019
Q1 | $3.11M | Sell |
13,893
-41,176
| -75% | -$8.5M | 0.13% | 204 |
|
|
2018
Q4 | $10.2M | Buy |
55,069
+12,470
| +29% | +$2.56M | 0.53% | 32 |
|
|
2018
Q3 | $10.6M | Buy |
42,599
+18,461
| +76% | +$4.48M | 0.39% | 73 |
|
|
2018
Q2 | $5.26M | Buy |
24,138
+3,030
| +14% | +$624K | 0.19% | 136 |
|
|
2018
Q1 | $4.04M | Sell |
21,108
-17,085
| -45% | -$3.15M | 0.15% | 180 |
|
|
2017
Q4 | $5.97M | Buy |
38,193
+30,116
| +373% | +$4.74M | 0.23% | 138 |
|
|
2017
Q3 | $1.26M | Sell |
8,077
-38,891
| -83% | -$6.15M | 0.05% | 386 |
|
|
2017
Q2 | $7.58M | Buy |
+46,968
| New | +$7.63M | 0.28% | 113 |
|
|
2016
Q4 | – | Sell |
-11,785
| Closed | -$1.33M | – | 983 |
|
|
2016
Q3 | $1.33M | Buy |
+11,785
| New | +$1.24M | 0.06% | 355 |
|
|
2015
Q2 | – | Sell |
-10,222
| Closed | -$790K | – | 1119 |
|
|
2015
Q1 | $790K | Buy |
+10,222
| New | +$795K | 0.03% | 466 |
|
|
2014
Q4 | – | Sell |
-10,890
| Closed | -$642K | – | 1105 |
|
|
2014
Q3 | $642K | Sell |
10,890
-1,816
| -14% | -$115K | 0.02% | 538 |
|
|
2014
Q2 | $849K | Buy |
+12,706
| New | +$808K | 0.02% | 535 |
|
|
2013
Q3 | – | Sell |
-5,428
| Closed | -$243K | – | 1107 |
|
|
2013
Q2 | $243K | Buy |
+5,428
| New | +$237K | 0.01% | 767 |
|
Other funds holding IDXX
VCM
VPM
Stevens Capital Management's IDXX Position: Q1 2026 in Review
Stevens Capital Management reduced its Idexx Laboratories (IDXX) stake by 68% in Q1 2026, selling an estimated $555K and leaving 406 shares worth $228K. The position accounts for 0.04% of the portfolio, ranked #206.
Stevens Capital Management first reported a position in IDXX in Q2 2013 and has held it in 31 quarters since. The position peaked at $10.6M in Q3 2018. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.
- Stevens Capital Management held 406 shares of Idexx Laboratories worth $228K as of Q1 2026.
- Stevens Capital Management sold 865 Idexx Laboratories shares in Q1 2026, an estimated $555K.
- Idexx Laboratories made up 0.04% of Stevens Capital Management's portfolio in Q1 2026, its #206 holding.
- Stevens Capital Management first reported a position in Idexx Laboratories in Q2 2013 and has held it in 31 quarters since.
- Stevens Capital Management's Idexx Laboratories position peaked at $10.6M in Q3 2018.
- 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.
Based on Stevens Capital Management's 13F filing for Q1 2026, filed 11 May 2026.